Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	6.34	-	-	-	-
Gross Profit	6.34	-	-	-	-
Selling, General & Admin	24.78	27	29.95	23.86	10.65
Research & Development	41.21	52.14	59.2	51.19	43.91
Operating Expenses	65.99	79.13	89.15	75.04	54.56
Operating Income	-59.65	-79.13	-89.15	-75.04	-54.56
Interest Expense	-0.1	-0.7	-0.8	-0.6	-0.6
Other Non Operating Income (Expenses)	2.44	3.43	1.73	-0.16	-0.06
EBT Excluding Unusual Items	-57.3	-76.4	-88.22	-75.8	-55.22
Merger & Restructuring Charges	-0.94	-	-	-	-
Pretax Income	-58.24	-76.4	-88.22	-75.8	-55.22
Net Income	-58.24	-76.4	-88.22	-75.8	-55.22
Net Income to Common	-58.24	-76.4	-88.22	-75.8	-55.22
Shares Outstanding (Basic)	54	27	27	6	1
Shares Outstanding (Diluted)	54	27	27	6	1
Shares Change (YoY)	94.62%	0.38%	388.59%	970.34%	27.97%
EPS (Basic)	-1.09	-2.78	-3.22	-13.52	-105.42
EPS (Diluted)	-1.09	-2.78	-3.22	-13.52	-105.42
Free Cash Flow	-18.41	-69.11	-77.59	-81.85	-38.28
Free Cash Flow Per Share	-0.34	-2.51	-2.83	-14.60	-73.08
Gross Margin	100.00%	-	-	-	-
Operating Margin	-940.18%	-	-	-	-
Profit Margin	-918.05%	-	-	-	-
Free Cash Flow Margin	-290.26%	-	-	-	-
EBITDA	-58	-77.23	-87.3	-73.55	-53.5
D&A For EBITDA	1.64	1.9	1.85	1.5	1.07
EBIT	-59.65	-79.13	-89.15	-75.04	-54.56
Revenue as Reported	6.34	-	-	-	-

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q